A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: the neuropsychiatric inventory median cutoff is a predictor of clinical outcome.

A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: the neuropsychiatric inventory median cutoff is a predictor of clinical outcome.

BACKGROUND: Although few placebo-controlled neuroleptic discontinuation studies have been conducted in people with dementia, such studies are essential to inform key clinical decisions. METHOD: A 3-month, double-blind, placebo-controlled, neuroleptic discontinuation study (June 2000 to June 2002) w...

Descripció completa

Dades bibliogràfiques
Autors principals:	Ballard, C, Thomas, A, Fossey, J, Lee, L, Jacoby, R, Lana, M, Bannister, C, Mcshane, R, Swann, A, Juszczak, E, O'Brien, J
Format:	Journal article
Idioma:	English
Publicat:	2004

Ítems similars

A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial).
per: Ballard, C, et al.
Publicat: (2008)

A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (The DART-AD Trial)
per: Ballard, C, et al.
Publicat: (2008)

A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (The DART-AD Trial)
per: Ballard, C, et al.
Publicat: (2008)

A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial).
per: Clive Ballard, et al.
Publicat: (2008-04-01)

Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial.
per: Ballard, C, et al.
Publicat: (2005)

Neuroleptic malignant syndrome after abrupt discontinuation of neuroleptic and anticholinergic drugs
per: Sameer Bhargava, et al.
Publicat: (2023-01-01)

Associations Between Neuropsychiatric Symptoms and Inflammation in Neurodegenerative Dementia: A Systematic Review
per: Swann P, et al.
Publicat: (2024-09-01)

The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial.
per: Ballard, C, et al.
Publicat: (2009)

Median channel shift less than the cutoff in flow cytometric crossmatch: Not to be ignored!
per: Pranav Dorwal, et al.
Publicat: (2017-01-01)

Cutoff criteria for the placebo response: a cluster and machine learning analysis of placebo analgesia
per: Per M. Aslaksen
Publicat: (2021-09-01)

The Best Cutoff Point for Median Nerve Cross Sectional Area at The Level of Carpal Tunnel Inlet
per: Payam Sarraf, et al.
Publicat: (2014-08-01)

Complications of neuroleptic hyperprolactinaemia
per: G. E. Mazo, et al.
Publicat: (2018-11-01)

Neuroleptic malignant syndrome
per: Mariana Moscovich, et al.
Publicat: (2011-10-01)

Neuroleptic malignant syndrome in a patient with moderate intellectual disability treated with olanzapine: A case report
per: Francesco Piacenza, et al.
Publicat: (2021-04-01)

A Double-Blind Randomized Placebo-Controlled Withdrawal Trial Comparing Memantine and Antipsychotics for the Long-Term Treatment of Function and Neuropsychiatric Symptoms in People With Alzheimer's Disease (MAIN-AD).
per: Ballard, C, et al.
Publicat: (2015)

Neuroleptic dosage for asian patients
per: Ismail, Rusli

Neuroleptic hyperprolactinemia medicamentous correction
per: L. N. Gorobets, et al.
Publicat: (2018-07-01)

Neuroleptic Malignant Syndrome and Methylphenidate
per: J Gordon Millichap
Publicat: (1998-12-01)

Parkinson disease and Neuroleptic withdrawal
per: Sulaiman Hatim, et al.
Publicat: (2010-04-01)

Wanna Get Away? Regression Discontinuity Estimation of Exam School Effects Away From the Cutoff
per: Angrist, Joshua, et al.
Publicat: (2018)

Exploring cutoff points and measurement invariance of the Brunnsviken brief quality of life inventory
per: Jón Ingi Hlynsson, et al.
Publicat: (2024-01-01)

Low dosage of aripiprazole induced neuroleptic malignant syndrome after interaction with other neuroleptic drugs
per: Albino Petrone, et al.
Publicat: (2013-09-01)

Neuropsychiatric Inventory domains cluster into neuropsychiatric syndromes in Alzheimer's disease: A systematic review and meta‐analysis
per: Shaun Kuan Wei Hiu, et al.
Publicat: (2022-09-01)

Association of caregiver demographic variables with neuropsychiatric symptoms in Alzheimer's disease patients for distress on the Neuropsychiatric Inventory (NPI)
per: Cláudia Godinho, et al.

Validity of the Brazilian version of the Neuropsychiatric Inventory Questionnaire (NPI-Q)
per: Ana Luiza Camozzato, et al.
Publicat: (2015-01-01)

MORPHOMETRIC ASPECTS OF NEUROLEPTIC CARDIOMYOPATHY MORPHOGENESIS
per: V. P. Volkov
Publicat: (2012-06-01)

Treatment of moderate neuroleptic malignant syndrome
per: Hossein Sanaei-Zadeh
Publicat: (2014-01-01)

Neuroleptic malignant syndrome in clinical practices
per: Bugarinović Snežana M., et al.
Publicat: (2016-01-01)

Olanzapine-Induced Neuroleptic Malignant Syndrome
per: Seyedhamze Hosseini, et al.
Publicat: (2017-05-01)

Clozapine Induced Neuroleptic Malignant Syndrome
per: Yong Suk Jo, et al.
Publicat: (2017-08-01)

Neuroleptic malignant syndrome for the emergency neurologist
per: Cristian Mihailescu
Publicat: (2010-09-01)

Use of neuroleptics in a general hospital
per: Castellanos Virgilio, et al.
Publicat: (2002-05-01)

Neuroleptic malignant syndrome: the diagnostic dilemma
per: Ivana Stasevic Karlicic, et al.
Publicat: (2016-07-01)

Treatment of neurolept-induced tardive dyskinesia
per: Jankelowitz SK
Publicat: (2013-09-01)

Discontinuous Economic Growing Quantity Inventory Model
per: Amir Hossein Nobil, et al.
Publicat: (2023-07-01)

Second generation antipsychotics causing neuroleptic malignant syndrome
per: C. Suraweera, et al.
Publicat: (2016-12-01)

The Neuropsychiatric Inventory-Diary Rating Scale (NPI-Diary): A Method for Improving Stability in Assessing Neuropsychiatric Symptoms in Dementia
per: Francesca Morganti, et al.
Publicat: (2018-09-01)

Impact of chosen cutoff on response rate differences between selective serotonin reuptake inhibitors and placebo
per: Alexander Lisinski, et al.
Publicat: (2022-04-01)

Validation Study of the Korean Version of the Brief Clinical Form of the Neuropsychiatric Inventory
per: Hee-Jin Kim, et al.
Publicat: (2016-06-01)

Dimensionality-reduction Procedure for the Capacitated p-Median Transportation Inventory Problem
per: Rafael Bernardo Carmona-Benítez
Publicat: (2020-03-01)